Trading biophama stocks before a catalyst event, if done correctly, can be a very profitable proposition. Some traders and investors who enjoy bringing more risk into play often times will hold through the actual catalyst event. While this does bring…
Tag: catalyst
Small Cap Biotechs That Could Make Big Moves This Week
Star Scientific (STSI) Star Scientific engages in the manufacture, distribution, and sale of consumer products, dietary supplements, and dissolvable tobacco. They also have several products which have a botanical-based component designed to treat a range of neurological conditions including Alzheimer’s…
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano, CFA which can be found at http://propthink.com/alexza-meaningfully-overvalued-following-its-latest-rally/4120
XenoPort Catalyst DD – December 31st
Catalyst: XenoPort conducted an End-of-Phase 2 meeting with the FDA in which it received feedback that a proposed development program for XP21279, a novel prodrug of levodopa, could support a potential New Drug Application (NDA) submission under Section 505(b)(2) of…
3 Small Cap Bio-Pharmas With Trade Catalysts And Speculation Investment Potential
Zogenix (ZGNX) engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the…
11/30/12 Catalyst Trade And Speculation Investment List
Alexza Pharma (NASDAQ: ALXA) Alexza engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes…
Huge Swing Trade Potential For Alexza Pharma With Two December Catalysts
Alexza Pharma (NASDAQ: ALXA) engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes an excipient-free…
